Table 1.
Clinical characteristics and body composition of non-obese and obese HIV-infected subjects
| Variable | Non-obese (n=35) | Obese (n=35) | p-value |
|---|---|---|---|
| Age, median years (IQR) | 45 (38, 49) | 46 (39, 51) | 0.61 |
| Female, % | 14 (40%) | 16 (46%) | 0.41 |
| Non-white, % | 18 (51%) | 20 (57%) | 0.63 |
| BMI, median kg/m2 | 23.9 (21.9, 26.5) | 35.6 (33.0, 40.1) | <0.001 |
| Smoker, % | 12 (34%) | 13 (37%) | 0.80 |
| Hepatitis C, % | 4 (11%) | 4 (11%) | NA |
| CD4 at enrollment, cells/µl | 621 (504, 924) | 758 (605, 966) | 0.08 |
| CD4% at enrollment | 36 (30, 40) | 38 (32, 42) | 0.15 |
| CD4 at ART initiation, cells/µl | 250 (142, 307) | 262 (132, 400) | 0.59 |
| Duration of ART treatment, years | 6.05 (4.33, 9.88) | 6.65 (4.42, 11.15) | 0.58 |
| DEXA body composition measurements | |||
| Bone mass, kg | 2.73 (2.21, 3.07) | 2.93 (2.54, 3.39) | 0.03 |
| Total lean mass, kg | 48. 4 (41.0, 55.4) | 56.2 (48.9, 65.9) | <0.001 |
| Fat mass, kg | 21.2 (14.8, 27.7) | 46.4 (37.9, 52.2) | <0.001 |
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; DEXA, dual-energy x-ray absorptiometry; IQR, interquartile range